Skip to main content
. 2017 Jun 29;13(6):e1005522. doi: 10.1371/journal.pcbi.1005522

Fig 3. Global influence of structural polypharmacology on therapy- and tumor-specific networks.

Fig 3

(A) Size of the networks. (B) Number of multi-target simulations performed in each network; the shade depicts the proportion of these that have an advantage >25% over the best individual seed interference. (C) Heat distribution, relative to the mild, ideal distribution of heat across nodes. (D) Advantage of the combination, compared to the best single seed (gene in bold in the list). The B01 and OV networks are laid out. Perturbed nodes are highlighted with a thick line, and heat is proportional to the size of the nodes (log scale). See [19] for tumor-type abbreviations. The ATC codes displayed refer to endocrine therapies (L02), antineoplastic agents (L01), sex hormones and modulators of the genital system (G03), anti-acne preparations (D10), antipsoriatics (D05) and antithrombotic agents (B01).